| Identification | Back Directory | [Name]
[2-(17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] propanoate | [CAS]
73771-04-7 | [Synonyms]
Regemt
HOE-777
Regenit
Dermatop
S-77-0777
Prednitop
PREDNICARBATE
Prednicarbate (200 mg)
Prednicarbate for system suitability
Prednicarbate for system suitability A
Prednisolone 17-(ethyl carbonate) 21-propionate
11β，17，21-Trihydroxypregna-1，4-diene-3，20-dione 17-(ethylcarbonate)-21-propionate
17-[(Ethoxycarbonyl)oxy]-11β-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
17-[(Ethoxycarbonyl)oxy]-11β-hydroxy-21-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione
(11β)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11b)-
[2-(17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] propanoate
[2-(17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl] propanoate | [EINECS(EC#)]
277-590-3 | [Molecular Formula]
C27H36O8 | [MDL Number]
MFCD00867445 | [MOL File]
73771-04-7.mol | [Molecular Weight]
488.57 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
110-112°; mp 183° | [alpha ]
D20 +63° (c = 0.1 in ethanol) | [Boiling point ]
640.7±55.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Practically insoluble in water, freely soluble in acetone and in ethanol (96 per cent), sparingly soluble in propylene glycol. It shows polymorphism (5.9). | [form ]
neat | [pka]
14.05±0.70(Predicted) | [color ]
White to Off-White | [InChIKey]
FNPXMHRZILFCKX-IVRISGIPNA-N | [SMILES]
[C@@]1(OC(=O)OCC)(C(=O)COC(=O)CC)CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C |&1:0,17,19,29,31,33,36,r| |
| Hazard Information | Back Directory | [Usage]
Topical anti-inflammatory agent. Glucocorticoid. | [Description]
Prednicarbate is a potent topical antiinflammatory agent with minimal systemic effects. It is useful in the treatment of cutaneous inflammatory disorders such as eczema and psoriasis. | [Description]
Prednicarbate is a synthetic corticosteroid and a derivative of prednisolone (Item No. 20866).1 It has anti-inflammatory activity comparable to that of desoximetasone in various murine models when administered topically but lacks activity when administered subcutaneously. Topical administration of prednicarbate (2 drops of a 0.1% solution per day) induces wound healing in hairless mice.2 Formulations containing prednicarbate have been used to treat chronic hand eczema.3 | [Chemical Properties]
White or almost white, crystalline powder. | [Originator]
Hoechst AG (W. Germany) | [Uses]
Topical anti-inflammatory agent. Glucocorticoid.
Prednicarbate (Dermatop E) is a synthetic nonfluorinated topical corticosteroid. | [Definition]
ChEBI: Prednicarbate is a corticosteroid hormone. | [Indications]
Prednicarbate (Dermatop E) is a synthetic nonfluorinated topical corticosteroid. | [Brand name]
Dermatop (Sanofi Aventis). | [General Description]
Prednicarbate, 17-[(ethoxycarbonyl)oxy]-11β-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione, is a prednisolone derivative with a C21 propionateester and a C17 ethyl carbonate group. It is availablefor use only in a 0.1% topical cream. Prednicarbate is amedium-potency GC. | [References]
[1] H G ALPERMANN H G V J Sandow. [Animal experiment studies on the topical and systemic effectiveness of prednisolone-17-ethylcarbonate-21-propionate].[J]. Zeitschrift fur Hautkrankheiten, 1986, 61 Suppl 1: 7-17.
[2] NICHOLAS S. BODOR Laszlo B Susan Tatar Kiss Buns. Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse[J]. Steroids, 1991, 56 8: Pages 434-439. DOI: 10.1016/0039-128x(91)90032-q
[3] STEPHANIE SOOST. Topical therapy of hand eczema – analysis of the prescription profile from dermatologists in private practice[J]. Journal Der Deutschen Dermatologischen Gesellschaft, 2011, 10 3: 180-184. DOI: 10.1111/j.1610-0387.2011.07787.x |
|
|